Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AAN 2022 | Proposal for an updated seizure classification framework in clinical trials

Claude Steriade, MD, New York School of Medicine, New York, NY, discusses a proposal for an updated seizure classification framework in clinical trials whereby seizures are the primary outcome. There have been several iterations of seizure classifications over the past years by the International League Against Epilepsy (ILAE). However, some terms that have been used in clinical trials have not always reflected the meaningful aspects of tracking seizure outcomes. Dr Steriade describes how they simplified the seizures that are trackable in a clinical trial to increase reliability. The members of the Epilepsy Study Consortium also looked at generalized epilepsies, and the types of seizures tracked in those trials and modified the existing classification to simplify it. Dr Steriade comments on addressing the future of patients who do not have countable seizures and suggests integrating complementary surrogate markers to improve rigor and reproducibility in those cases. This interview took place at the American Academy of Neurology 2022 Congress in Seattle, WA.

Disclosures

Dr Steriade receives consulting fees for activities performed for The Epilepsy Study Consortium, which are paid directly to NYU to contribute to her salary. Dr Steriade receives grants from the NIH, Dorris Duke Foundation, NORD, and institutional entities (CTSI, Parekh Centre).